Table 1.

Baseline characteristics in FOLFIRI bevacizumab and FOLFIRI cetuximab, in FIRE-3 RAS WT and miR-pop populations

FIRE-3 RAS WTmiR-pop
Bevacizumab (n = 201)Cetuximab (n = 199)Bevacizumab (n = 176)Cetuximab (n = 164)
Gender
 Female68 (34%)53 (27%)61 (35%)42 (26%)
 Male133 (66%)146 (73%)115 (65%)121 (74%)
Age, y
 ≤65105 (52%)104 (52%)90 (51%)88 (54%)
 >6596 (48%)95 (48%)86 (49%)76 (46%)
 Median (y)65646564
BRAF status
 WT176 (88%)176 (88%)155 (88%)143 (87%)
 Mutant25 (12%)23 (12%)21 (12%)21 (13%)
Number of metastatic sites
 182 (41%)85 (43%)77 (44%)73 (45%)
 ≥2118 (59%)112 (57%)99 (56%)90 (55%)
 Median2222
ECOG score
 0109 (54%)107 (54%)93 (53%)87 (53%)
 189 (44%)89 (45%)80 (45%)76 (46%)
 23 (2%)3 (1%)3 (2%)1 (1%)
Tumor sidedness
 Left+rectum149 (75%)157 (81%)132 (79%)128 (80%)
 Right50 (25%)38 (19%)36 (21%)31 (20%)
miR-31-3p
 Low (<cutoff)121 (69%)108 (66%)
 High (≥cutoff)55 (31%)56 (34%)
 Mean (SD)1.52 (2.43)1.58 (2.28)
 Median0.580.73
 Min - Max0.01–200.01–17.31
  • NOTE: Percentages calculated on patients without missing data (13 missing for sidedness, 1 missing for gender, 1 for number of metastatic sites). Percentages calculated on patients without missing data (miR-pop: 13 missing for sidedness, 1 missing for gender, 1 for number of metastatic sites/FIRE-3 RAS WT: 2 missing for number of metastatic sites, 6 missing for sidedness).